UNSPSC 51283959: Benzylsulfamide

This classification denotes a topical anti-infective agent with the molecular formula C13H14N2O2S, a preparation that US FDA regulates as an active ingredient or moiety under Unique Ingredient Identifier AI9WDT80FQ, chemically known as sulfanilamide, n(sup 4)-benzyl- but more generally known as benzylsulfamide, which bears US NIH Compound Identifier 66909. European Medicines Agency schedules Benzylsulfamide in its eXtended EudraVigilance Medicinal Product Dictionary or XEVMPD under Index SUB05773MIG.

The term BENZYLSULFAMIDE is an International Non-Proprietary Name or INN (see World Health Organization INN reference publication, Volume 16, No. 3 1962, List 4). BENZYLSULFAMIDE is scheduled in the U.S. International Trade Commission's Harmonized Tariff System (HTS) Pharmaceutical Appendix. SMILES: S(=O)(=O)(NCC1CCCCC1)C1CCC(N)CC1.

UNSPSC 51283959 Benzylsulfamide is a Commodity code that shows minimal recent state and local procurement activity directly aligned with its narrow chemical definition. The recent opportunities posted under this code—naloxone procurement, direct-to-manufacturer prescription programs, fire department medical supplies, and cooperative pharmaceutical purchasing—represent health care products and programs that do not involve benzylsulfamide as a specified input or end-use item. The code appears to have been applied to these solicitations as a catch-all pharmaceutical or medical-supply classifier rather than as a specific chemical commodity purchase.

State and local buyers are primarily health agencies, fire departments, and cooperative purchasing vehicles across Florida, Texas, Minnesota, and multi-state jurisdictions. Issuing bodies include Seminole County's public health function (IFB for naloxone and drug deactivation systems, due July 26, 2023), the Texas Health and Human Services Commission (RFI for direct-to-manufacturer prescription programs, April 3, 2026), the City of Tampa Fire Department via competitive bid for medical and first aid supplies ($700,000 estimated contract, due March 13, 2026), and the Minnesota Multistate Cooperative Purchasing Alliance (RFP for generic multi-source pharmaceuticals and OTC products, response deadline March 26, 2026). The code shows no evidence of solicitations specifically for benzylsulfamide or products containing it as a primary component. Business development professionals should verify category assignment with issuing authorities before pursuing opportunities posted under this code, as the mismatch between the code's chemical specificity and the actual scope of recent buys suggests either miscoding or use of this code as a pharmaceutical general classifier that does not reliably predict future benzylsulfamide demand.